Salute e Benessere

SKYLINEDX ANNOUNCES NEW PUBLICATION ON SKY92 GENE EXPRESSION PROFILING TEST in…

This combined approach allows clinicians to more accurately identify patients with ultra-high-risk profiles, paving the way for improved risk-adapted treatment strategies. These findings reinforce the value of SKY92 as a critical tool in the evolving landscape of multiple myeloma prognostication and personalized treatment planning. This combined approach allows clinicians to more accurately identify patients with ultra-high-risk profiles, paving the way for improved risk-adapted treatment…

NOTICE OF ANNUAL GENERAL MEETING OF BIORETEC LTD

A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation. A proxy representative shall present a dated power of attorney or, in another reliable manner, demonstrate their right to represent the shareholder. A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation. A proxy representative shall present a dated power of attorney or, in another...

MolecuLight Showcases Advanced Wound Care Imaging at 2025 CAMPS Meeting

"Our technology addresses a critical need in wound care by providing clinicians with the ability to see what they otherwise couldn't," said Anil Amlani, CEO at MolecuLight. "By visualizing bacterial presence, we can help support the efficacy of advanced therapies such as CAMPs, improve patient outcomes, and ultimately reduce the burden of chronic wounds." "Our technology addresses a critical need in wound care by providing clinicians with the ability to see what they…

Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class…

PD1 targeted antibodies drive the differentiation of effector CD8(+) T cells into terminally exhausted status. In the latest pre-clinical experiment conducted by Fapon Biopharma, FP008 effectively counteracted this process through IL-10M, significantly reducing the anti-PD-1 antibody-mediated exhaustion of CD8(+) T cells. In mouse experiments, FP008 exhibited potent anti-tumor effects, significantly increased the infiltration of intratumoral CD8(+) T cells, reduced their terminal…

MAGic™ BioProcessing welcomes a new team member

For more information, please contact:Peter Karlberg, [email protected] For more information, please contact: Peter Karlberg, [email protected] or visit our webpagehttps://magicbioprocessing.com About MAGic™ BioProcessing MAGic BioProcessing (Lab-on-a-Bead AB) is a biotech tools company from Uppsala,Swedenthat develops and sells proprietary magnetic-based products and methods for bioprocessing of biologics such as recombinant proteins,...

NTG Nordic Transport Group A/S - 2024 Annual Report Conference Call

NTG Nordic Transport Group A/S - 2024 Annual Report Conference CallWe expect to release the 2024 Annual Report of NTG Nordic Transport Group in the evening of March 5, 2025. A webcast and conference call will be held in the morning of March 6, 2025, at 9:30 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Christian Jakobsen will present the 2024 Annual Report. The presentation will be followed by a Q&A session.Date:March 6, 2025Time:9:30 am CET To...

Orchard Therapeutics Announces Reimbursement Agreement in Spain

MLD is an ultra-rare, rapidly progressive, irreversible and ultimately fatal neurometabolic disease caused by an error in the gene responsible for encoding the enzyme arylsulfatase A (ARSA) leading to neurological damage and developmental regression. In the most severe form of MLD, babies develop normally but in late infancy start to rapidly lose the ability to walk, talk and interact with the world around them. These children eventually deteriorate into a vegetative state, which may require...

Casino Group: Release of the FY 2024 presentation results

RELEASE OF THE FULL YEAR 2024 EARNINGS PRESENTATION The Group has released its full-year 2024 earnings presentation on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2025/02/2025-02-28-Presentation-FY-2024-Results.pdfANALYST AND INVESTOR CONTACTSCharlotte Izabel– [email protected] – +33 (0)6 89 19 88 [email protected] – +33 (0)1 53 65 24 17 PRESS CONTACTSCasino Group –...

Casino Group: 2024 Full-Year Results

2024 FULL-YEAR RESULTSAfter the 2024 transformation, the New Casino is now committed to implementing its convenience retail strategy Financial restructuring and change of controlRefocusing on convenience retail in FranceSale of Casino hypermarkets and supermarkets: 366 stores sold in 2024Employment Protection Plans implemented Governance changes at MonoprixRenouveau 2028 strategic plan launched and steering committees created to lead its implementation...

Global High Potency Active Pharmaceutical Ingredients Market to Surpass USD 45…

Key Takeaways from the High Potency Active Pharmaceutical Ingredients Market Report Key Takeaways from the High Potency Active Pharmaceutical Ingredients Market Report To read more about the latest highlights related to the HPAPI market, get a snapshot of the key highlights entailed in theGlobal High Potency Active Pharmaceutical Ingredients Market Report High Potency Active Pharmaceutical Ingredients Overview High-potency active pharmaceutical ingredients are a category of...

Endo Presents Healthcare Provider Survey at Joint Meeting of International…

The Endo-sponsored presentation is below: The Endo-sponsored presentation is below: About Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy. 1 It is estimated that PD can affect as many as 1 in 10 men in the U.S., 2 but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help. 3 PD in men may...

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Cash and cash equivalents totaled €81.8 million as of December 31, 2024Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen's Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 27, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of...

/C O R R E C T I O N -- Across Global Alliance/

SINGAPORE, Feb. 27, 2025 /PRNewswire/ -- Across Global Alliance, a strategic alliance of clinical research organizations (CROs) and Specialist Service Providers has selected oomnia®, Wemedoo's advanced clinical trial data management system, as its centralized digital infrastructure. This strategic decision aims to streamline clinical trial management, enhance real-time collaboration among alliance members, and ensure regulatory compliance in over 90 countries. SINGAPORE , Feb. 27, 2025 ...

Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its…

The Debenture matures two (2) years from the date of issuance (the "Maturity Date"), will bear interest at the rate of 10% per annum and is convertible into common shares of Innocan ("Common Shares") prior to the Maturity Date at a price of $0.21 per share (based on a foreign exchange rate on the day prior to the date of conversion). The Debenture will be secured by a general security agreement and related security interest filed under the laws of the Province of Alberta as…

Across Global Alliance Selects Wemedoo's oomnia® as Central Clinical Trial…

After an extensive evaluation of available solutions, oomnia emerged as the only system capable of meeting the alliance's complex operational needs. By integrating essential clinical trial functions, including EDC, CTMS, RTSM, and eTMF into a single, unified platform, oomnia eliminates inefficiencies caused by fragmented systems and disjointed data workflows. After an extensive evaluation of available solutions, oomnia emerged as the only system capable of meeting the alliance's complex…

Spineway marks its return to Arab Health 2025 with new distribution agreements

Press release Ecully, February 27, 2025 – 6.30 p.m.Spineway marks its return to Arab Health 2025with new distribution agreements Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 2025 edition of the Arab Health trade fair, which was held at the Dubai World Trade Centre from January 27 to 30, 2025. This unmissable event for the medical sector in the Middle East offered Spineway the chance to strengthen its presence...

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and…

Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET.An investor webcast and conference call will be held to discuss the results on the same day.Date: Tuesday, March 4, 2025 Time: 14:00 CET / 13:00 GMT / 08:00 EST The call will start with presentations by senior management, followed by a Q&A session. Live Webcast (audio + slides):The live webcast can be accessed from the Idorsia websitewww.idorsia.com. Dial-in...

Dermal Fillers Market Size Worth $7.58 Billion, Globally, by 2031 Growing at…

To explore the valuable insights in the Dermal Fillers Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00002992/ To explore the valuable insights in the Dermal Fillers Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00002992/ The Dermal Fillers market report provides a comprehensive analysis of the growing Dermal Fillers market, highlighting trends,...

Bacterial Vaginosis Drug Market to Surge to $3.82 Billion by 2031, Fuelled by…

To explore the valuable insights in the Bacterial Vaginosis Drug Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00018820/ To explore the valuable insights in the Bacterial Vaginosis Drug Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00018820/ The Bacterial Vaginosis Drug market report provides a comprehensive analysis of the growing Bacterial...

DPCR & qPCR Market Size Worth 18.23 billion by 2030 | Growing 9.3% CAGR…

The report provides a data-driven analysis, combining both qualitative and quantitative insights to highlight current market trends and future projections. It also offers actionable information, helping companies develop strategies to drive growth and expand in North America, Europe, or Asia-Pacific. With a global perspective, the research enables businesses to understand diverse healthcare market demands and stay ahead of the competition. A sample of the report is available for preview…

Dry Eye Products Market Size Worth 10.04 billion by 2030 | Growing at 4.7% CAGR…

To explore the valuable insights in the Dry Eye Products Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00012323/ To explore the valuable insights in the Dry Eye Products Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00012323/ The dry eye products market is experiencing significant growth owing to rising geriatric population and growing awareness...

Veterinary Dermatology Market to Hit US$30.31 Billion by 2030 with 8.5% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=195447184 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=195447184 Browse in-depth TOC on 'Veterinary Dermatology Market' 340 - Tables 84 - Figures 384 - Pages U.S. Veterinary Dermatology Market: The U.S. dominates the North American veterinary dermatology market due to its strong pet healthcare infrastructure and high spending on animal health. The increasing...

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

The article continued: The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC) has launched a global initiative to support new projects aimed at improving cancer detection technologies. According to DelveInsight Business Research, the global cancer therapy market is projected to expand at a compound annual growth rate (CAGR) of 9.12%, reaching an estimated value of $285.96 billion by 2030. The article continued: TheCenter for Innovation and...

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

In addition, EpiVax has filed a new Model Master File (MMF) for its PANDA® In Silico Model to the FDA, supporting regulatory filing of Abbreviated New Drug Applications (ANDA) of generic peptide drugs. EpiVax's PANDA® MMF provides detailed descriptions of its models and methodologies for assessing the immunogenicity of peptide drugs and their impurities and can now be referenced as a Drug Master File (DMF) in FDA ANDA fillings. The accessibility of EpiVax's PANDA® MMF represents an important…

Altri Comunicati